880485-40-5

Upstream product

• 506-93-4 guanidine nitrate 
• 14385-65-0 1-(4-chlorophenyl)-3-(furan-2-yl)-2-propen-1-one 
• 14385-65-0 (2E)-1-(4-chlorophenyl)-3-(2-furyl)prop-2-en-1-one 
• 50-01-1 guanidine hydrochloride 
• 98-01-1 furfural 
• 104-88-1 4-chlorobenzaldehyde 
• 111042-59-2 3-(4-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one 
• 1192-62-7 1-(2-furyl)-1-ethanone 

Downstream Products

• 1392402-43-5 C₂₁H₁₅ClN₄O 
• 1392402-44-6 C₂₇H₁₉ClN₆O₂ 
• 1392402-45-7 C₂₆H₁₈ClN₇O₂ 
• 1446751-96-7 C₂₂H₁₆ClN₃O₂ 
• 1446752-16-4 C₂₄H₁₇Cl₂N₃O₃ 
• 1446752-06-2 C₂₄H₁₈ClN₃O₃ 

Relevant academic research and scientific papers

Ultrasound-mediated synthesis, biological evaluation, docking and in vivo acute oral toxicity study of novel indolin-2-one coupled pyrimidine derivatives

The work reports ultrasound-mediated greener synthesis of 11 novel 3-(4-(4-chlorophenyl)-6-(substituted phenyl/heteryl)pyrimidin-2-ylimino)indolin-2-one (7a–7k) derivatives. The synthesized derivatives were evaluated for their in vitro anticancer activity against a panel of selected human cancer cell lines of breast (MCF-7), cervix (HeLa), prostate (PC-3) and lung (A-549). Among the tested compounds, 7b exhibited most promising in vitro anticancer activity against HeLa, PC-3 and A-549 with GI50 value 15.38, 19.67 and 4.37?μM, respectively. The compounds (7a–7k) were also screened for induction of apoptosis and morphological changes in cancer cells at their GI50 concentration. The treatment of HeLa, PC-3 and A549 cancer cells with 7b and treatment of MCF-7 cancer cells with 7h showed apoptosis and morphological changes such as cell shrinkage, cell wall deformation and reduced number of viable cells. The compound 7b has shown almost 5.00 times more selectivity for PC-3 cancer cell lines in comparison to the RWPE-1 normal prostate epithelial cells. Molecular docking study has been carried out, which replicates results of biological activity in cases of initial hits 7b, 7c and 7d, suggesting that these compounds have a potential to become lead molecules in the drug discovery process. In silico ADMET study was performed for predicting pharmacokinetic properties and toxicity profile of the synthesized compounds and expressed good oral drug-like behaviour. An in vivo acute oral toxicity study was performed using Swiss albino mice for the most active compounds 7b and 7c, and results indicate that the compounds are non-toxic in nature.

Synthesis and biological evaluation of some new 4-aryl-1-(4,6-diaryl pyrimidine)-2-azetidinone by conventional and microwave methods and their biological activities

4-Aryl-1-(4,6-diaryl pyrimidine)-2-azetidinone/4-aryl-3-chloro-1-(4,6- diaryl pyrimidine)-2-azetidinone were prepared by reaction of appropriate 2-(methoxy phenylideneamino)-4-diaryl pyrimidine (Schiff base) and acetyl chloride/chloroacetylchloride in dim

Synthesis and evaluation of some novel [1,2,4]triazolo[1,5-α] pyrimidine derivatives for anticancer activity

A series of 7-(4-chlorophenyl)-2-phenyl-1,7-dihydro [1,2,4] triazolo [1,5α] pyrimidine 4a-l have been synthesized and evaluated for anticancer activity. The newly synthesized compounds have been characterized by IR, 1H NMR and elemental analyse

Anti-bacterial and anti-leishmanial studies of 4, 6-diarylpyrimidin-2- amines

Seven new chalcones along with nine already reported ones were synthesized from aryl aldehydes and substituted acetophenones by Claisen-Schmidt condensation. Each chalcone was treated with guanidine hydrochloride followed by oxidation with H2O